Conduit Pharmaceuticals Income Tax Expense Over Time
| CDTTW Stock | 0.01 0.0002 1.83% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Conduit Pharmaceuticals Performance and Conduit Pharmaceuticals Correlation. Conduit |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Conduit Pharmaceuticals. If investors know Conduit will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Conduit Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (3.22) |
The market value of Conduit Pharmaceuticals is measured differently than its book value, which is the value of Conduit that is recorded on the company's balance sheet. Investors also form their own opinion of Conduit Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Conduit Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Conduit Pharmaceuticals' market value can be influenced by many factors that don't directly affect Conduit Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Conduit Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Conduit Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Conduit Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Income Tax Expense Analysis
Compare Conduit Pharmaceuticals and related stocks such as Equillium, DiaMedica Therapeutics, and Valneva SE ADR Income Tax Expense Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EQ | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 140.5 K | (23 K) | (45 K) | (72 K) | 45.3 M | 580 K | 551 K |
| DMAC | 69.9 K | 12.6 K | 2.7 K | 7.7 K | 42.3 K | 12.4 K | 22.3 K | (9 K) | 80 K | 31 K | 27 K | 28 K | 28 K | 43 K | 45.2 K |
| VALN | (176 K) | 26 K | 96 K | 348 K | 334 K | 224 K | 356 K | 1.1 M | 88 K | 874 K | (909 K) | 3.4 M | (1.5 M) | 2.8 M | 2.9 M |
| VANI | 9.3 K | 9.3 K | 9.3 K | 42.2 K | (6.9 M) | 58 K | 31 K | 93 K | 86 K | 362 K | 147.7 K | (641 K) | (7.4 M) | (6.6 M) | (6.3 M) |
| DNLI | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (3.1 M) | 10.1 M | (351 K) | 823 K | (575 K) | 21 K | 30 K | 28.5 K |
| DNTH | 236 K | 236 K | 236 K | 236 K | 236 K | 236 K | 236 K | 236 K | 2.4 M | 6.2 M | 7.5 M | (2 M) | (1.3 M) | 187.1 K | 177.8 K |
| DOMH | 100 K | 14.5 K | 385 K | 2.6 M | (48 K) | 40.3 M | 456 K | (225 K) | (6.5 M) | (1.5 M) | 5.6 M | (252 K) | 16.5 M | 300 K | 285 K |
| VCEL | (1.3 M) | (18.7 M) | (4.2 M) | (5.3 M) | (3.6 M) | (257 K) | 2.6 M | 1.1 M | 3.4 M | (1.8 M) | 180 K | (111 K) | 721 K | 814 K | 854.7 K |
| VCNX | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 3 M | 1.3 M | (1.8 M) | 152 K | 458 K | 852 K | (93 K) | (48.9 K) | (46.5 K) |
| VCYT | 819 K | 819 K | (2 K) | (2.9 M) | (664 K) | 518 K | 3 M | 5.4 M | 1.2 M | 3.9 M | 938 K | (6.1 M) | 133 K | (2.2 M) | (2.1 M) |
Conduit Pharmaceuticals and related stocks such as Equillium, DiaMedica Therapeutics, and Valneva SE ADR Income Tax Expense description
My Equities
My Current Equities and Potential Positions
| Conduit Pharmaceuticals | CDTTW |
| Classification | Pharmaceutical Products |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
null 0.0107
Additional Tools for Conduit Stock Analysis
When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.